A5085643279- Epigenetics and DNA Methylation
- Histone Deacetylase Inhibitors Research
- Cancer-related gene regulation
- Cancer, Lipids, and Metabolism
- MicroRNA in disease regulation
- Regulation of Appetite and Obesity
- Cancer-related molecular mechanisms research
- Adipose Tissue and Metabolism
- Cancer, Stress, Anesthesia, and Immune Response
- Cancer, Hypoxia, and Metabolism
- Adipokines, Inflammation, and Metabolic Diseases
- Peptidase Inhibition and Analysis
- Cell Adhesion Molecules Research
- Diabetes Treatment and Management
- Cancer-related Molecular Pathways
- Trace Elements in Health
- Cancer Mechanisms and Therapy
- Advanced biosensing and bioanalysis techniques
- RNA Interference and Gene Delivery
- Immune responses and vaccinations
- Atherosclerosis and Cardiovascular Diseases
- Mitochondrial Function and Pathology
- Cancer Cells and Metastasis
- CRISPR and Genetic Engineering
- Metabolomics and Mass Spectrometry Studies
National Cancer Institute
2022-2023
Center for Cancer Research
2020-2023
National Institutes of Health
2020-2023
National Institute of Allergy and Infectious Diseases
2022
Morehouse School of Medicine
2016-2020
Emory University
2017
Bipar
2017
Creative Research Enterprises (United States)
2017
University of Alabama at Birmingham
2010
University of Chicago
1976
// Adriana Harbuzariu 1 , Antonio Rampoldi Danielle S Daley-Brown Pierre Candelaria Tia L Harmon Crystal C Lipsey Derrick J Beech 2 Alexander Quarshie 3 Gabriela Oprea Ilies 4 Ruben R Gonzalez-Perez Department of Microbiology, Biochemistry and Immunology, Morehouse School Medicine, Atlanta, GA, 30310 USA Surgery, Biomedical Informatics Program Master Science in Clinical Research Program, Center, GA 30310, Pathology Laboratory Emory University Grady Memorial Hospital, 30303 Correspondence to:...
Estrogen-receptor-negative breast cancer (BCER-) is mainly treated with chemotherapeutics. Leptin signaling can influence BCER- progression, but its effects on patient survival and chemoresistance are not well understood. We hypothesize that leptin decreases the of patients by, in part, inducing expression chemoresistance-related genes. The correlation receptor (OBR), leptin-targeted genes (CDK8, NANOG, RBP-Jk), (BC) was determined from Cancer Genome Atlas (TCGA) mRNA data. Leptin-induced...
Abstract Histone deacetylase inhibitors (HDACi) are part of a growing class epigenetic therapies used for the treatment cancer. Although HDACis effective in T-cell lymphomas, solid tumors with this drugs has not been successful. Overexpression multidrug resistance protein P-glycoprotein (P-gp), encoded by ABCB1, is known to confer HDACi romidepsin vitro, yet increased ABCB1 expression associated patients, suggesting that other mechanisms arise clinic. To identify alternative romidepsin, we...
AIMTo develop a leptin peptide receptor antagonist linked to nanoparticles and determine its effect on viability of breast cancer cells. METHODSThe antagonist, LPrA2, was coupled via EDAC carbodiimide] iron oxide (IONP-LPrA2) increase efficacy.IONP-LPrA2 conjugation confirmed by Western blot nanoparticle tracking analysis.Human triple negative (TNBC) MDA-MB-231, HCC1806 estrogen positive (ER + ) MCF-7 cells were analyzed for the expression receptor, Ob-R.The effects levels leptin-induced...
ABSTRACT Histone deacetylase inhibitors (HDACis) are part of a growing class epigenetic therapies used for the treatment cancer. While elevated levels efflux pump P-gp associated with in vitro resistance to romidepsin, this mechanism does not translate clinic. We developed romidepsin-resistant cell line independent function that acts upstream deacetylation process. found expression methyltransferase METTL7A is necessary resistance, and naïve cells can drive thiol-containing HDACis....
<p>Supplemental Table S8 contains information about METTL7A and METTL7B in T-cell lymphoma tissue microarray samples</p>
<p>Supplemental Table S2 contains information about the cross-resistance profile of MCF7 DpVp300 cells for multiple drugs</p>
<p>Figure S2 contains cell cycle analysis and cytotoxicity data for MCF7 DpVp300 cells showing they are resistant to romidepsin do not overexpress P-gp</p>
<p>Figure S1 contains chemical structures of select HDAC inhibitors</p>
<p>Supplemental Table S8 contains information about METTL7A and METTL7B in T-cell lymphoma tissue microarray samples</p>
<p>Supplemental Table S7 contains information about the normal tissue expression of METTL7A and METTL7B</p>
<p>Figure S3 contains gene ontology analysis, motif and nucleosome density from the RNA-seq ATAC-seq data.</p>
<p>Figure S4 contains cytotoxicity assay and immunoblot data from the MCF7 DpVp300 cell lines showing that expression of METTL7A confers resistance.</p>
<p>Figure S1 contains chemical structures of select HDAC inhibitors</p>
<p>Supplemental Table S1 contains information about the chemical structures of HDACi</p>
<p>Figure S2 contains cell cycle analysis and cytotoxicity data for MCF7 DpVp300 cells showing they are resistant to romidepsin do not overexpress P-gp</p>
<div>Abstract<p>Histone deacetylase inhibitors (HDACi) are part of a growing class epigenetic therapies used for the treatment cancer. Although HDACis effective in T-cell lymphomas, solid tumors with this drugs has not been successful. Overexpression multidrug resistance protein P-glycoprotein (P-gp), encoded by <i>ABCB1</i>, is known to confer HDACi romidepsin <i>in vitro</i>, yet increased <i>ABCB1</i> expression associated patients,...
<div>Abstract<p>Histone deacetylase inhibitors (HDACi) are part of a growing class epigenetic therapies used for the treatment cancer. Although HDACis effective in T-cell lymphomas, solid tumors with this drugs has not been successful. Overexpression multidrug resistance protein P-glycoprotein (P-gp), encoded by <i>ABCB1</i>, is known to confer HDACi romidepsin <i>in vitro</i>, yet increased <i>ABCB1</i> expression associated patients,...
<p>Figure S6 contains cell cycle analysis of cells overexpressing METTL7A.</p>
<p>Figure S4 contains cytotoxicity assay and immunoblot data from the MCF7 DpVp300 cell lines showing that expression of METTL7A confers resistance.</p>